<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="10351"><DrugName>nikkomycin Z</DrugName><DrugSynonyms><Name><Value>nikkomycin Z</Value></Name><Name><Value>SP-920704</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>nik-Z</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>59456-70-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14455">Bayer AG</CompanyOriginator><CompaniesPrimary><Company id="1056721">Valley Fever Solutions Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="14455">Bayer AG</Company><Company id="19868">Shaman Pharmaceuticals Inc</Company><Company id="20527">University of Arizona</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10351" type="Drug"><TargetEntity id="273398" type="siDrug">Neopolyoxin C</TargetEntity></SourceEntity><SourceEntity id="1056721" type="Company"><TargetEntity id="5035526679" type="organizationId">Valley Fever Solutions Inc</TargetEntity></SourceEntity><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity><SourceEntity id="19868" type="Company"><TargetEntity id="4295914911" type="organizationId">Shaman Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="20527" type="Company"><TargetEntity id="4298217968" type="organizationId">University of Arizona</TargetEntity></SourceEntity><SourceEntity id="1109" type="ciIndication"><TargetEntity id="10017543" type="MEDDRA"></TargetEntity><TargetEntity id="D003881" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="124" type="ciIndication"><TargetEntity id="10017533" type="MEDDRA"></TargetEntity><TargetEntity id="D009181" type="MeSH"></TargetEntity><TargetEntity id="-2109353222" type="omicsDisease"></TargetEntity><TargetEntity id="817" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1323" type="ciIndication"><TargetEntity id="B38" type="ICD10"></TargetEntity><TargetEntity id="007.2" type="ICD9"></TargetEntity><TargetEntity id="10009825" type="MEDDRA"></TargetEntity><TargetEntity id="D003048" type="MeSH"></TargetEntity><TargetEntity id="-1258232365" type="omicsDisease"></TargetEntity><TargetEntity id="1161" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1748" type="Action"><TargetEntity id="1508" type="Mechanism">Homoserine Dehydrogenase (Fungal) Inhibitors</TargetEntity><TargetEntity id="1059" type="Mechanism">Efflux Pump (Fungal) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1323">Coccidioides infection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1109">Dermatomycosis</Indication><Indication id="124">Fungal infection</Indication><Indication id="53">Candida albicans infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="6626">Chitin synthase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1748">Fungicide</Action><Action id="15178">Systemic dermatological antifungal product</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D1A2</Code><Name>Systemic dermatological antifungals</Name></Ephmra><Ephmra><Code>J2</Code><Name>SYSTEMIC AGENTS FOR FUNGAL INFECTIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-11T08:57:43.000Z</LastModificationDate><ChangeDateLast>2019-06-11T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;The &lt;ulink linkID="20527" linkType="Company"&gt;University of Arizona&lt;/ulink&gt;, at its Valley Fever Center for Excellence, in conjunction with &lt;ulink linkID="1056721" linkType="Company"&gt;Valley Fever Solutions&lt;/ulink&gt;, is developing the chitin synthase inhibitor nikkomycin Z (nik-Z), for the potential use in the treatment of  coccidioidomycosis (valley fever) [&lt;ulink linkID="1126471" linkType="Reference"&gt;1126471&lt;/ulink&gt;], [&lt;ulink linkID="1130288" linkType="Reference"&gt;1130288&lt;/ulink&gt;], [&lt;ulink linkID="1628427" linkType="Reference"&gt;1628427&lt;/ulink&gt;].  In June 2019, scaled up trial material was in process. At that time, a  proof of concept phase IIa trial    in sick humans and a pivotal trial  were expected to begin in early 2020 and in the fourth quarter of 2020, respectively   [&lt;ulink linkID="2161147" linkType="Reference"&gt;2161147&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Shaman Pharmaceuticals licensed the azole antifungal compound, nikkomycin, from &lt;ulink linkID="14455" linkType="Company"&gt;Bayer&lt;/ulink&gt; for the potential treatment of systemic mycoses in 1995. Although the compound was taken into a phase I trial and has an active IND with the FDA, the compound is not presently under active development and is available for license [&lt;ulink linkID="327384" linkType="reference"&gt;327384&lt;/ulink&gt;]. The rights to the compound were acquired by the University of Arizona in 2005 [&lt;ulink linkID="1130529" linkType="Reference"&gt;1130529&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In October 2014, the US FDA designated Qualified Infectious Disease Product (QIDP) and Fast Track status for the treatment of coccidioidomycosis [&lt;ulink linkID="1622216" linkType="Reference"&gt;1622216&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2018,  a phase IIa proof of concept trial was planned to begin in early 2019 and pivotal trial in May 2019. At that time, proof of concept trial data were expected in the fourth quater of 2019 [&lt;ulink linkID="2069971" linkType="Reference"&gt;2069971&lt;/ulink&gt;]. In January 2019, the company met with the US FDA to review the  drug for the phase II trial [&lt;ulink linkID="2138521" linkType="Reference"&gt;2138521&lt;/ulink&gt;]. In June 2019, a  proof of concept phase IIa trial    in sick humans was expected to begin in early 2020 and a pivotal trial in the fourth quarter of 2020 [&lt;ulink linkID="2161147" linkType="Reference"&gt;2161147&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, a clinical study of nikkomycin Z was planned to assess the improvement in coccidioidomycosis patients (expected n= 48) with pneumoniaÂ compared to placebo treatment [&lt;ulink linkID="1628427" linkType="Reference"&gt;1628427&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, the company expected data from a proof-of-concept trial in September 2014. At that time, the company planned to initiate a pivotal trial in summer 2015 [&lt;ulink linkID="1548140" linkType="Reference"&gt;1548140&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2010, data from a randomized, double-blind, placebo-controlled phase I study (&lt;ulink linkID="43394" linkType="Protocol"&gt;NCT00834184&lt;/ulink&gt;; VFCE-2008-002), started in October 2008, were presented at the 50th ICAAC meeting in Boston, MA. Healthy volunteers (n=32) were treated with multiple oral doses of nikkomycin Z or placebo for 14 days. The drug was found to be well tolerated with no serious adverse events reported. Good pharmacokinetic data were seen. The elimination rate constant was found not to be dependent on dose. Cmax and AUC were not significantly different for the 750 mg 12h and 750 mg 8 h regimens (AUC 34.5 vs 35.6 microg.h/ml) but the 8 h regimen was found to provide a 50% higher exposure per 24 h. The study was completed in January 2010 [&lt;ulink linkID="1126471" linkType="Reference"&gt;1126471&lt;/ulink&gt;], [&lt;ulink linkID="1130288" linkType="Reference"&gt;1130288&lt;/ulink&gt;], [&lt;ulink linkID="1130514" linkType="Reference"&gt;1130514&lt;/ulink&gt;]. At that time,  following further manufacturing of nikkomycin Z, further trials were to be initiated in 2011 [&lt;ulink linkID="1130362" linkType="Reference"&gt;1130362&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, a phase I/II study (&lt;ulink linkID="10548" linkType="Protocol"&gt;NCT00614666&lt;/ulink&gt;; VCFE-2007-001) of the safety and pharmacokinetics of nikkomycin Z in Coccidioides pneumonia patients (n=6) was initiated, in collaboration with the &lt;ulink linkID="1043079" linkType="Company"&gt;FDA Office of Orphan Products&lt;/ulink&gt;. At the time completion was expected in October 2010; however, by August 2009, the study had been terminated due to recruitment challenges and lack of funding [&lt;ulink linkID="1130519" linkType="Reference"&gt;1130519&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;&lt;ulink linkID="10351" linkType="Drug"&gt;&lt;/ulink&gt;In September 2011,  data from Swiss-Webster mice studies were presented at the 51st ICAAC meeting in Chicago, IL. Nikkomycin Z showed a dose-dependent response over the range of 20 to 80 mg/kg/day and was more effective than fluconazole when treatment was delayed 48 h. Drug related tolerance problems were not observed in uninfected mice treated with nikkomycin Z. Treatment for 21 days was found to be slightly more effective than that for 7 days.  The Cmax, AUC and half-life values of nikkomycin Z were 11.2 microg/ml, 7.25 microg.h/ml and 0.419 h in the 10 mg/kg sc group, 49.5 microg/ml, 27.2 microg.h/ml and 0.347 h in the 40 mg/kg sc group and 3.67 microg/ml, 14.3 microg.h/ml and 2.1 h respectively with 52.6% bioavailability in the 40 mg/kg, po group [&lt;ulink linkID="1219981" linkType="Reference"&gt;1219981&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Nikkomycin Z selectively inhibits chitin synthase and is most effective against those fungi with high levels of chitin [&lt;ulink linkID="277184" linkType="reference"&gt;277184&lt;/ulink&gt;]. In murine models, the compound is orally active against a variety of mycoses, but is particularly active against the less common endemic mycoses, ie, coccidioidomycosis, histoplasmosis and blastomycosis [&lt;ulink linkID="180183" linkType="reference"&gt;180183&lt;/ulink&gt;]. It is effective in candidiasis when delivered by sustained release or continuous infusion. In vitro, nikkomycin Z has a pronounced synergistic interaction with azoles, such as &lt;ulink linkID="44292" linkType="Drug"&gt;fluconazole&lt;/ulink&gt;, against a number of non-filamentous fungi [&lt;ulink linkID="275110" linkType="reference"&gt;275110&lt;/ulink&gt;]. There is also synergistic interaction with the echinocandins [&lt;ulink linkID="327385" linkType="reference"&gt;327385&lt;/ulink&gt;], inhibitors of glucan synthesis, particularly against several filamentous fungi, such as Aspergillus fumigatus [&lt;ulink linkID="277184" linkType="reference"&gt;277184&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Several patents have been issued relating to the use of nikkomycin A for the treatment of mycoses, ie, US-04851389, US-04914087, US-05006513, US-05019560, US-05091375, US-05096889, US-05134126, US-05149795, US-05194427, US-05330976 and US-05789387. The use of nikkomycin Z for the treatment of candidiasis is claimed in US-05789387 [&lt;ulink linkID="327384" linkType="reference"&gt;327384&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Nafsika H Georgopapadakou, DuPont Pharmaceuticals, Wilmington, DE, USA&lt;br/&gt;                                                                                                                             &lt;br/&gt;28 April 1999&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="10351"&gt;Nikkomycin Z&lt;/ulink&gt;, discovered in 1976, is a peptidyl nucleoside antibiotic related to polyoxins [&lt;ulink linkType="reference" linkID="326310"&gt;326310&lt;/ulink&gt;]. The compound, and also that of the related compound, nikkomycin X, were produced by Streptomyces tendae Tu 901 [&lt;ulink linkType="reference" linkID="326310"&gt;326310&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt; &lt;/subtitle&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Several &lt;ulink linkType="Drug" linkID="10351"&gt;nikkomycin Z&lt;/ulink&gt; derivatives have been produced by directed fermentation and chemical synthesis, but none have shown an overall superior activity to &lt;ulink linkType="Drug" linkID="10351"&gt;nikkomycin Z&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="326302"&gt;326302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="10351"&gt;Nikkomycin Z&lt;/ulink&gt; is a potent, selective inhibitor of chitin synthases in several fungi, with typical Ki values of 1 to 4 microM [&lt;ulink linkType="reference" linkID="254447"&gt;254447&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="254435"&gt;254435&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="254352"&gt;254352&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="277184"&gt;277184&lt;/ulink&gt;]. In the non-pathogenic yeast, Saccharomyces cerevisiae, and possibly other fungi [&lt;ulink linkType="reference" linkID="326313"&gt;326313&lt;/ulink&gt;], some selectivity for chitin synthase 3 was observed [&lt;ulink linkType="reference" linkID="254420"&gt;254420&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="178901"&gt;178901&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="10351"&gt;Nikkomycin Z&lt;/ulink&gt; enters the fungal cells via a dipeptide transport system, and this is typically the source of nikkomycin resistance [&lt;ulink linkType="reference" linkID="326316"&gt;326316&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="254370"&gt;254370&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In murine models, it is orally active against a variety of mycoses, but is particularly active against the less common endemic mycoses, ie, coccidioidomycosis, histoplasmosis and blastomycosis, with comparable activity to the azoles [&lt;ulink linkType="reference" linkID="180183"&gt;180183&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="254435"&gt;254435&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="254352"&gt;254352&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="92312"&gt;92312&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="308175"&gt;308175&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="271003"&gt;271003&lt;/ulink&gt;]. It is effective in candidiasis when delivered by sustained release or continuous infusion. In vitro, &lt;ulink linkType="Drug" linkID="10351"&gt;nikkomycin Z&lt;/ulink&gt; has a pronounced synergistic interaction with azoles, such as &lt;ulink linkType="Drug" linkID="44292"&gt;fluconazole&lt;/ulink&gt;, against a number of non-filamentous fungi [&lt;ulink linkType="reference" linkID="275110"&gt;275110&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="326320"&gt;326320&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="112503"&gt;112503&lt;/ulink&gt;]. There is also synergistic interaction with the echinocandins [&lt;ulink linkType="reference" linkID="327385"&gt;327385&lt;/ulink&gt;], inhibitors of glucan synthesis, particularly against several filamentous fungi, such as Aspergillus fumigatus [&lt;ulink linkType="reference" linkID="277184"&gt;277184&lt;/ulink&gt;]. In addition, &lt;ulink linkType="Drug" linkID="10351"&gt;nikkomycin Z&lt;/ulink&gt; inhibits the adhesion of Candida albicans to epithelial cells [&lt;ulink linkType="reference" linkID="326323"&gt;326323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism &lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="10351"&gt;Nikkomycin Z&lt;/ulink&gt; is rapidly degraded by plasma esterases [&lt;ulink linkType="reference" linkID="271006"&gt;271006&lt;/ulink&gt;]. A pharmacokinetic study in mice demonstrated that &lt;ulink linkType="Drug" linkID="10351"&gt;nikkomycin Z&lt;/ulink&gt; is rapidly elimintated after intravenous infusion. However, its absorption after oral administration was sufficiently slow, allowing inhibitory levels to persist for over 2 h [&lt;ulink linkType="reference" linkID="92312"&gt;92312&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;A pharmacokinetic study in dogs has revealed that the half-life for elimination from plasma is 1.6 to 2.8 h, for oral administration, and 1.5 to 2.8 h for intravenous administration; these values are not affected by dose. The oral bioavailability ranged from 9.4% to 13.4% [&lt;ulink linkType="reference" linkID="285442"&gt;285442&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="10351"&gt;Nikkomycin Z&lt;/ulink&gt; was well-tolerated at the doses tested [&lt;ulink linkType="reference" linkID="92312"&gt;92312&lt;/ulink&gt;]. No further data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Trials in healthy volunteers demonstrated an average half-life of 2.2 h for &lt;ulink linkType="Drug" linkID="10351"&gt;nikkomycin Z&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="293817"&gt;293817&lt;/ulink&gt;]. Although the compound has undergone a clinical trial and has an active IND with the FDA, the compound is not currently under active development [&lt;ulink linkType="reference" linkID="327384"&gt;327384&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and Contraindications&lt;/subtitle&gt;No serious adverse events were encountered in single doses of up to 2 g [&lt;ulink linkType="reference" linkID="293817"&gt;293817&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;	&lt;/subtitle&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Although &lt;ulink linkType="Drug" linkID="10351"&gt;nikkomycin Z&lt;/ulink&gt; is the most active of the peptidyl nucleoside antibiotics, this compound has modest antifungal activity, as a single agent in comparison to established antifungal agents. It is also susceptible to transport-associated resistance. Its potential for combination therapy with azoles and echinocandins is diminished by its instability in plasma and the fact that both azoles and echinocandins have clinical utility as single agents and are under patent protection. Complex and costly, combination trials for such a modest agent at the end of its patent life may not be viable.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1056721">Valley Fever Solutions Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1323">Coccidioides infection</Indication><StatusDate>2010-09-12T00:00:00.000Z</StatusDate><Source id="1126471" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20527">University of Arizona</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1323">Coccidioides infection</Indication><StatusDate>2007-09-30T00:00:00.000Z</StatusDate><Source id="1130519" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1999-06-14T00:00:00.000Z</StatusDate><Source id="327384" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19868">Shaman Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1999-06-09T00:00:00.000Z</StatusDate><Source id="327384" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1109">Dermatomycosis</Indication><StatusDate>1999-06-14T00:00:00.000Z</StatusDate><Source id="327384" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19868">Shaman Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="53">Candida albicans infection</Indication><StatusDate>1999-06-09T00:00:00.000Z</StatusDate><Source id="327384" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19868">Shaman Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1997-02-01T00:00:00.000Z</StatusDate><Source id="236244" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19868">Shaman Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="53">Candida albicans infection</Indication><StatusDate>1996-10-14T00:00:00.000Z</StatusDate><Source id="220853" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19868">Shaman Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1995-06-01T00:00:00.000Z</StatusDate><Source id="178785" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1109">Dermatomycosis</Indication><Source id="180183" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20527">University of Arizona</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1323">Coccidioides infection</Indication><StatusDate>2007-09-30T00:00:00.000Z</StatusDate><Source id="1130519" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20527">University of Arizona</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>2005-01-31T00:00:00.000Z</StatusDate><Source id="1130529" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1056721">Valley Fever Solutions Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>2005-01-31T00:00:00.000Z</StatusDate><Source id="1130362" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1995-06-13T10:33:51.000Z</StatusDate><Source id="178785" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="20527">University of Arizona</OwnerCompany><Country id="US">US</Country><Indication id="1323">Coccidioides infection</Indication><AwardedIndication>Treatment of coccidioidomycosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-10-02T00:00:00.000Z</MileStoneDate><Source id="1622216" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1056721">Valley Fever Solutions Inc</OwnerCompany><Country id="US">US</Country><Indication id="1323">Coccidioides infection</Indication><AwardedIndication>Treatment of coccidioidomycosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-02-14T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="12">Qualified Infectious Disease Product</RegulatoryDesignation><OwnerCompany id="29298">Melinta Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="1323">Coccidioides infection</Indication><AwardedIndication>Coccidioidomycosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-10-02T00:00:00.000Z</MileStoneDate><Source id="1622216" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00445"><Name>Chitin synthase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2138521" linkType="reference" linkID="2138521"&gt;2138521&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1056721">Valley Fever Solutions Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14455">Bayer AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="19868">Shaman Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20527">University of Arizona</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H]([C@@H](c1ccc(cn1)O)O)[C@@H](C(=O)N[C@@H]([C@@H]2[C@H]([C@H]([C@@H](O2)n3ccc(=O)[nH]c3=O)O)O)C(=O)O)N</Smiles></StructureSmiles><Deals><Deal id="124339" title="Shaman to develop Bayer's nikkomycin Z "/><Deal id="131945" title="University of Arizona to develop Bayer's nikkomycin Z"/><Deal id="131946" title="University of Arizona to receive funding from the FDA for nikkomycin Z development"/><Deal id="135669" title="US Government to fund Valley Fever Solutions' clinical development of nikkomycin Z for early coccidioidal pneumonia       "/></Deals><PatentFamilies><PatentFamily id="2014590" number="EP-00367954" title="Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics."/><PatentFamily id="2088538" number="EP-00330923" title="Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics."/><PatentFamily id="2801769" number="US-20140275511" title="Purification of nikkomycin Z"/><PatentFamily id="3525985" number="CN-106259462" title="A bactericidal composition and use thereof"/><PatentFamily id="3530479" number="CN-106337073" title="A culture medium and method for improving fermentation yield of nikkomycin"/><PatentFamily id="3655587" number="CN-106701867" title="A method for improving yield of nikkomycin"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Valley Fever Solutions Inc" id="1056721"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mudanjiang Baijiaxin Biotechnology Co Ltd" id="1147337"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>